Passer au contenu principal

Subventions financées

Filtrer par:
Effacer les filtres
Filtrer par:

6 résultats trouvés

Correlating quaternary structure of pathological protein aggregates with phenotypic presentation of ALS

Amyotrophic lateral sclerosis (ALS) is a disease of progressive weakness that leads to death within a few years of onset.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Québec
DATE DE DÉBUT
2024

Developing machine learning models of disease progression and survival outcomes in ALS patients: evaluating the utility of structural brain MRI as an ALS biomarker

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder with no known cure, leading to progressive loss of motor function and ultimately the death of the patient.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Québec
DATE DE DÉBUT
2024

Gold and BBB Opening in ALS (The GOALS Trial): A Phase 2a, Open-label, Single-arm Clinical Trial of Oral CNM-Au8 Coupled with Primary Motor Cortex Blood Brain Barrier Opening Using Transcranial MR-guided Focused Ultrasound in Amyotrophic Lateral Sclerosis

Rationale: Mitochondrial dysfunction has been identified as a contributing factor for bioenergetic dysregulation and neurodegeneration in the motor cortex and spinal cord of patients with ALS.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022

Quantitative PET/MR Imaging of Brain Derived Neurotrophic Factor (BDNF) / Tropomyosin Related Kinase B (TRKB) signaling in ALS – decoding a potential pathogenetic pathway

Brain derived neurotrophic factor (BDNF) is well recognized for its neuroprotective functions, via activation of its high affinity receptor, tropomysin related kinase B (TrkB).


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Alberta
DATE DE DÉBUT
2022

Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS

Amyotrophic lateral sclerosis (ALS) is a terminal disease that paralyzes people because the brain is no longer able to communicate with the muscles that we are typically able to move at will.


TYPE DE SUBVENTION
Subventions de plateforme
Domaine de recherche
Neurodégénérescence
Province
Alberta
DATE DE DÉBUT
2021

Novel MRI biomarkers for monitoring disease progression in ALS

For this project Dr. Sanjay Kalra and his team aims to improve on current techniques to use magnetic resonance imaging (MRI) as a readily available way to examine if a potential new treatment is working to slow down progression of ALS.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Alberta
DATE DE DÉBUT
2016